Search the Newsreel

Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch

Earnings Call Insights: Atea Pharmaceuticals (AVIR) Q2 2026 MANAGEMENT VIEW * "The positive top line results from C-BEYOND, our Phase III trial evaluating the combination of bemnifosbuvir for the treatment of hepatitis C in North America represents a significant milestone for Atea" (Founder, Chairman, …

Atea Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2026-08-12

ATEA Pharmaceuticals ($AVIR) reported its Q2 2026 earnings, posting a loss of -$0.41 per share, significantly beating analyst estimates of -$0.57. The company's revenue matched estimates at $0. The article also details recent hedge fund activity for AVIR, showing institutional investors adding and decreasing …

Atea Pharmaceuticals Reports Q2 2026 Financials and Clinical Progress in Form 10-Q Filing

Atea Pharmaceuticals has filed its Q2 2026 Form 10-Q report, detailing its financial status, including 80,204,699 shares outstanding as of August 10, 2026. The company is actively pursuing two antiviral programs: the C-FORWARD Phase 3 clinical trial for Hepatitis C (HCV) with BEM/RZR, and …

Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.15 EPS

Atea Pharmaceuticals (NASDAQ:AVIR) announced its quarterly earnings, reporting an EPS of ($0.41), surpassing the consensus estimate of ($0.56) by $0.15. The company's shares traded at $5.06, and it has a market capitalization of approximately $405 million. Analyst sentiment is divided, with one Strong Buy …

Atea Pharmaceuticals (NASDAQ: AVIR) advances HCV Phase 3 as losses widen

Atea Hepatitis C Regimen Posts 93.9% Sustained Response

Atea Pharmaceuticals reported Q2 2026 financial results, including a net loss of $32.9 million, and provided a business update highlighting progress in its viral hepatitis pipeline. The Phase 3 C-BEYOND trial for its HCV regimen (BEM/RZR) met primary and secondary non-inferiority endpoints with a …

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Atea Pharmaceuticals announced its second-quarter 2026 financial results, highlighting positive Phase 3 C-BEYOND trial results for BEM/RZR in treating HCV, which met primary and secondary endpoints. The company also provided updates on its C-FORWARD trial, expected in early Q1 2027, and advancements in its …

Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks

This article identifies three promising penny stocks: Atea Pharmaceuticals (AVIR), Mammoth Energy Services (TUSK), and Tilly's (TLYS), highlighting their financial health and growth potential in a rising market. Atea Pharmaceuticals is noted for its strong cash position and positive trial results despite being pre-revenue. …

Arrowstreet Capital Limited Partnership Takes Position in Atea Pharmaceuticals, Inc. $AVIR

Arrowstreet Capital Limited Partnership has acquired a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), purchasing 210,542 shares valued at approximately $1.13 million. This acquisition makes Arrowstreet Capital Limited Partnership one of several institutional investors increasing their stakes in the biopharmaceutical company, which now has …

Atea Pharmaceuticals, Inc. (AVIR) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Atea Pharmaceuticals, Inc. (AVIR) stock, including its current price, news, and historical data. It details the company's financial performance, analyst insights, and key statistics, along with a company profile outlining its biopharmaceutical focus. The page …

Atea's Aug. 12 webcast will include a business update

Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results and provide a business update. Investors can access the webcast through the Investor Relations …

Atea Pharmaceuticals to Host Second Quarter 2026 Financial

Atea Pharmaceuticals announced it will host a conference call and audio webcast on August 12, 2026, to report its second-quarter 2026 financial results and provide a business update. The event will cover the company's progress in developing oral antiviral therapeutics for serious viral diseases. …

301,699 Shares in Atea Pharmaceuticals, Inc. $AVIR Bought by Irenic Capital Management LP

Irenic Capital Management LP recently acquired 301,699 shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) for approximately $1.62 million, increasing institutional ownership in the company to 86.67%. This purchase occurred as Atea Pharmaceuticals reported a quarterly loss of $0.57 per share, outperforming analyst estimates. The stock …

Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Atea Pharmaceuticals Inc (AVIR), noting its current valuation score of 6.78, ranking it 260 out of 385 in the Biotechnology & Medical Research industry. It highlights AVIR's current P/E ratio of -2.22, which is significantly below its recent …

Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Thursday

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR)

The article highlights bullish sentiments from analysts on several healthcare stocks, including Opko Health (OPK), Atea Pharmaceuticals (AVIR), and Monte Rosa Therapeutics (GLUE). H.C. Wainwright and Piper Sandler reiterated Buy ratings for Opko Health, William Blair maintained a Buy rating for Atea Pharmaceuticals, and …

Atea drops despite late-stage trial win for hepatitis C therapy

Atea Pharmaceuticals (AVIR) announced positive topline data from its Phase 3 C-BEYOND study for its lead candidate BEM/RZR, demonstrating a late-stage trial win against chronic hepatitis C. Despite this clinical success, the company's stock traded lower on Tuesday. The drug is an antiviral therapy …

Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus

Atea Pharmaceuticals announced positive topline results from its C-BEYOND Phase 3 trial, showing its bemnifosbuvir/ruzasvir (BEM/RZR) combination achieved statistical non-inferiority against the standard treatment for chronic hepatitis C virus (HCV) infection. The BEM/RZR regimen demonstrated robust sustained virologic response rates, including in cirrhotic and …

Atea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Results for Bemnifosbuvir/Ruzasvir in Hepatitis C, Achieving Non-Inferiority to Epclusa

Atea Pharmaceuticals announced positive results from its C-BEYOND Phase 3 clinical trial, demonstrating that bemnifosbuvir/ruzavir (BEM/RZR) achieved non-inferiority compared to standard-of-care sofosbuvir/velpatasvir (SOF/VEL) for chronic hepatitis C. BEM/RZR showed a high sustained virologic response rate of 93.9% with a shorter 8-week treatment duration for …

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Atea Pharmaceuticals announced positive topline results from its Phase 3 C-BEYOND trial, demonstrating that its BEM/RZR treatment for hepatitis C virus (HCV) achieved statistical non-inferiority compared to a standard-of-care treatment. The study showed high cure rates, with a 93.9% sustained virologic response, and highlighted …

AVIR|Atea Pharmaceuticals Inc|Price:4.810|Chg%:+0.080

This article provides a comprehensive stock analysis of Atea Pharmaceuticals Inc (AVIR), detailing its TradingKey Stock Score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. Key insights highlight the company's stable fundamentals, high growth potential, fair valuation, and strong institutional …

Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Atea Pharmaceuticals Inc (AVIR), but notes that relevant data for business segments and regional revenue have not yet been disclosed by the company for fiscal years 2020 through 2022. It briefly shows the company's current …

Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Atea Pharmaceuticals Inc (AVIR), highlighting its current earnings forecast score and analyst ratings. Based on three analysts, the average price target for AVIR is $6.00, with a consensus "Buy" rating. The article also discusses past EPS performance …

[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus

Atea Pharmaceuticals has announced the start of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat hepatitis E virus (HEV). The trial will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, including single and …

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Atea Pharmaceuticals has announced the initiation of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat hepatitis E virus (HEV). This marks a significant step towards addressing the unmet medical need for HEV, especially in immunocompromised individuals, …

William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating

William Blair has reiterated its Buy rating for Atea Pharmaceuticals (AVIR.US). The article does not provide further details on the rationale behind this rating or any specific financial analysis.